Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dose and concentration-effect relations for rilmenidine.

C T Dollery1, D S Davies, J Duchier

  • 1Department of Clinical Pharmacology, Royal Postgraduate Medical School, London, England.

The American Journal of Cardiology
|February 24, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clusters of vascular aging manifestations predict incident cardiovascular events in the community.

Nature communications·2026
Same author

Adapted educational health program among deprived subjects with prediabetes.

Primary care diabetes·2022
Same author

Prediabetes and deprivation: A couple at high risk of diabetes.

Revue d'epidemiologie et de sante publique·2021
Same author

Body Silhouette Trajectories Over the Lifespan and Insomnia Symptoms: The Paris Prospective Study 3.

Scientific reports·2019
Same author

Perceived stress is inversely related to ideal cardiovascular health: The Paris Prospective Study III.

International journal of cardiology·2018
Same author

[Silhouettes at different age of life: Retrospective appreciation of corpulence and his impact on prevalence of hypertension at 60years].

Annales de cardiologie et d'angeiologie·2017

Rilmenidine, an alpha 2 agonist, effectively lowers blood pressure in a dose-dependent manner. Lower doses (0.5 and 1 mg) avoid side effects like orthostatic hypotension, making it a potentially safer antihypertensive option.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Trials

Background:

  • Alpha 2 agonists are known for their antihypertensive properties.
  • Understanding the dose-response relationship of new agents is crucial for therapeutic application.

Purpose of the Study:

  • To evaluate the dose-effect and concentration-effect relationships of rilmenidine.
  • To assess hemodynamic and side-effect responses to single oral doses of rilmenidine.

Main Methods:

  • Two double-blind studies were conducted in healthy subjects and hypertensive patients.
  • Rilmenidine was administered at doses of 0.5, 1, 2, and 3 mg, with placebo as a control.
  • Blood pressure, heart rate, sedation, and dry mouth were measured; plasma concentrations were assayed.

Related Experiment Videos

Main Results:

  • Antihypertensive and sedative effects correlated directly with rilmenidine dose and plasma concentration.
  • Lower doses (0.5 and 1 mg) did not cause orthostatic hypotension, significant heart rate decrease, or significant dry mouth.
  • Sedation effects at lower doses were inconsistent between healthy and hypertensive subjects.

Conclusions:

  • Rilmenidine demonstrates dose-dependent blood pressure reduction in both normotensive and hypertensive individuals.
  • Lower doses of rilmenidine appear to offer a favorable safety profile regarding orthostatic hypotension and dry mouth.
  • Further investigation may be needed to clarify dose-specific sedation effects.